Browse the evidence

Men experience greater magnitude of weight loss and cardiometabolic improvement (insulin sensitivity, lipids) from low-calorie diets than women, but women maintain these benefits better during weight maintenance due to lower metabolic rebound.

If you are a woman, expect your initial weight loss on a strict low-calorie diet to be slower than a man's, but recognize that your body may be better at keeping your blood fats and insulin sensitivity stable once you stop dieting. Focus on the long-term maintenance of health markers rather than just the scale number during the first 8 weeks.

Combination therapy with half-dose rosiglitazone and metformin significantly reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance compared to placebo.

If you have impaired glucose tolerance, combining half-dose rosiglitazone (2mg) and metformin (500mg) twice daily significantly reduces your risk of developing type 2 diabetes (66% relative risk reduction) compared to placebo. This regimen is effective and appears safe with few side effects.

Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.

Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.

Liraglutide (a GLP-1 receptor agonist) significantly reduces the risk of major adverse cardiovascular events (MACE) and cardiovascular death in patients with type 2 diabetes and high cardiovascular risk.

If you have type 2 diabetes and are at high risk for heart problems (like existing heart disease or multiple risk factors), adding liraglutide to your standard care can significantly lower your risk of heart attack, stroke, and death from cardiovascular causes. It is taken as a daily injection. While it can cause stomach issues, the cardiovascular benefits are substantial for this high-risk group.

Once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes at high cardiovascular risk, demonstrating both noninferiority and superiority over placebo.

If you have type 2 diabetes and are at high risk for heart problems, once-weekly semaglutide injections can significantly lower your risk of heart attack, stroke, or cardiovascular death compared to placebo. The treatment involves a gradual dose increase to minimize side effects like nausea, which are common but usually mild and temporary. The cardiovascular benefits are substantial and well-supported by a large, rigorous clinical trial.

Obesity is associated with a significantly higher incidence of endometrial cancer compared to normal weight, with a relative risk of 3.22 for obese women.

For women, maintaining a healthy weight is particularly important for reducing the risk of endometrial cancer. Obesity more than triples the risk compared to normal weight. Weight management is a key preventive strategy.

Insulin resistance is a multisystem disorder that predisposes individuals to both cardiovascular disease and type 2 diabetes, often manifesting as the metabolic syndrome (abdominal obesity, atherogenic dyslipidemia, hypertension, glucose intolerance, and prothrombotic state).

If you have high blood pressure, high cholesterol, and high blood sugar, you likely have insulin resistance. This cluster of conditions, called the metabolic syndrome, significantly increases your heart disease risk. The most effective strategy is to address the root cause: improve your insulin sensitivity through weight loss, physical activity, and dietary changes, rather than just managing each number in isolation.

Excess visceral adipose tissue is a primary driver of cardiometabolic risk, independent of total body fat or BMI, by causing insulin resistance, atherogenic dyslipidemia, and inflammation.

Do not rely on BMI alone to assess your health risk. If you have a large waist circumference, especially combined with high triglycerides, you may have dangerous visceral fat even if your weight is normal. Prioritize reducing abdominal fat through lifestyle changes, as this specific fat type drives heart disease and diabetes risk more than total body weight does.

In the pathogenesis of type 2 diabetes, defects in both insulin action (resistance) and insulin secretion (dysfunction) occur early during the transition from normal glucose tolerance to impaired glucose tolerance, and both must be targeted for effective intervention.

If you are at risk for type 2 diabetes (e.g., prediabetes), focusing solely on one aspect of metabolic health is likely insufficient. You must address both how your body uses insulin (resistance) and how well your pancreas produces it (secretion). This typically involves lifestyle interventions that improve sensitivity (like exercise and weight management) while also supporting pancreatic function (often through weight loss and reducing metabolic stress). Early intervention is critical because these defects worsen over time.

Obesity and PCO have a synergistic deleterious effect on glucose tolerance, leading to higher fasting and post-load glucose levels and increased basal hepatic glucose production compared to either condition alone.

For women with PCO who are also obese, the risk of developing type 2 diabetes is significantly higher than for obese women without PCO. This is due to a 'double hit' of hormonal resistance and excess weight. Aggressive management of both insulin sensitivity and weight is crucial.

Intensive glycemic therapy (targeting near-normal glucose levels) significantly reduces the development and progression of microvascular complications (retinopathy, nephropathy, neuropathy) and cardiovascular disease in patients with type 1 diabetes compared to conventional therapy.

For people with Type 1 Diabetes, aiming for near-normal blood sugar levels through intensive insulin therapy (multiple daily injections or a pump) significantly reduces the risk of eye, kidney, nerve, and heart complications over the long term. While this approach increases the risk of low blood sugar events, it does not harm cognitive function or quality of life. The key is individualizing the regimen to fit your lifestyle while striving for lower HbA1c targets.

Bariatric surgery induces high rates of type 2 diabetes remission and prevention, with effects persisting for at least 10-15 years, although some relapse occurs over time.

Bariatric surgery is highly effective at putting type 2 diabetes into remission, with most patients achieving remission within two years. While some patients may experience a return of diabetes over 10 years, the long-term risk of developing diabetes remains significantly lower than in non-surgical patients. Surgery is a powerful tool for diabetes management and prevention.

Obesity increases the risk of cardiovascular disease and hypertension through mechanisms involving increased visceral fat, insulin resistance, and altered sympathetic nervous system activity.

Managing your body weight, especially visceral fat, is crucial for heart health. Obesity increases your risk of cardiovascular disease and hypertension through multiple mechanisms, including insulin resistance and altered sympathetic nervous system activity. Losing weight can significantly reduce this risk.

Skeletal muscle hypertrophy is primarily regulated by the balance between protein synthesis and degradation, driven by the IGF1-Akt-mTOR pathway (positive regulator) and the myostatin-Smad2/3 pathway (negative regulator).

To build muscle, you need to stimulate the IGF1-Akt-mTOR pathway (via resistance training and adequate protein) while minimizing the inhibitory effects of myostatin. It's not just about eating enough to 'stop' loss; active signaling drives the growth.

Pharmacological treatment of hypertension significantly reduces major cardiovascular events, including heart failure, stroke, and mortality, regardless of baseline blood pressure levels.

If diagnosed with hypertension, adhere to prescribed pharmacological treatment. Fixed-dose combinations are often recommended to improve adherence and minimize side effects. The reduction in cardiovascular risk is substantial and consistent across different baseline risks.

Total sleep time and sleep efficiency are significantly modulated by the circadian phase, being highest when the scheduled sleep episode coincides with the falling and plateau phases of the core body temperature rhythm, and lowest when it coincides with the rising phase.

For the most consolidated sleep, schedule your main sleep block during the time when your body temperature is falling and at its lowest (typically late night/early morning). Avoid scheduling long sleep blocks when your body temperature is rising (late afternoon/early evening), as this leads to shorter, less efficient sleep.

Chronic low-grade inflammation in adipose tissue, driven by M1 macrophage infiltration and pro-inflammatory cytokine secretion (TNF-α, IL-1β, IL-6), directly causes insulin resistance and contributes to the pathogenesis of Type 2 Diabetes.

For obese individuals, reducing body fat is critical not just for weight loss, but to reduce the chronic inflammation in fat tissue that blocks insulin. This inflammation directly impairs how your body uses glucose, increasing the risk of Type 2 Diabetes. Weight loss interventions that reduce this inflammation can improve insulin sensitivity.

Testosterone administration in eugonadal men causes a dose-dependent decrease in HDL cholesterol and an increase in hemoglobin, while having no significant effect on PSA, sexual function, or spatial cognition at the doses studied.

Higher doses of testosterone will lower your 'good' cholesterol (HDL) and raise your hemoglobin. While PSA and sexual function remain stable, the cardiovascular risk profile changes with dose. Lower doses (125mg) may offer a better balance of muscle gain vs. lipid impact than the highest doses (600mg).

Obesity is a major risk factor for cancer, accounting for approximately 20% of all malignancies, with the strongest evidence linking it to endometrial, esophageal adenocarcinoma, colorectal, postmenopausal breast, prostate, and renal cancers.

Maintain a healthy body weight through diet and physical activity, as excess adiposity is a proven driver for several common cancers. Focus on reducing visceral fat, as abdominal obesity is strongly linked to higher cancer mortality.

Obesity increases the risk of postmenopausal estrogen receptor-positive (ER+) breast cancer and is associated with worse disease outcomes and higher mortality across all breast cancer subtypes.

For postmenopausal women, maintaining a healthy weight is critical to reducing the risk of developing estrogen-receptor-positive breast cancer and improving survival rates if diagnosed. This is achieved through lifestyle interventions that lower circulating estrogens and inflammatory markers.

Muscle hypertrophy is driven by the PI3K-AKT-mTOR pathway, where IGF-1 and insulin signaling promote protein synthesis and inhibit degradation, while myostatin/activin signaling via Smad2/3 inhibits growth.

To build muscle, your body relies on specific hormonal signals like IGF-1 and insulin to activate the mTOR pathway, which drives protein synthesis and blocks breakdown. Conversely, myostatin acts as a brake on growth. Understanding this balance explains why resistance training (which stimulates these pathways) is effective, while conditions that elevate myostatin or impair insulin signaling can hinder growth.

Central fat distribution (waist-to-hip ratio) is independently associated with insulin hypersecretion, particularly in women, but is not related to insulin sensitivity after adjusting for BMI.

For women, carrying weight around the waist is linked to higher insulin production, even if your blood sugar regulation (sensitivity) is normal. This suggests that central obesity drives hormonal demand. Weight loss strategies that reduce waist circumference may help lower insulin levels, but the primary driver of metabolic health in obesity appears to be the total amount of insulin secreted, not just where the fat is stored.

Elevated levels of triglyceride-rich lipoproteins (TRL) and their remnants are causally associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction, ischemic stroke, and aortic valve stenosis, independent of LDL cholesterol levels.

High triglycerides are not just a number; they represent particles that directly contribute to heart disease. If your triglycerides are consistently above 1.2 mmol/L (100 mg/dL), you have elevated cardiovascular risk, even if your LDL is normal. Managing this involves dietary changes to reduce carbohydrate and alcohol intake, and potentially medication if lifestyle changes are insufficient, especially if you have diabetes or existing heart disease.

Apolipoprotein CIII (apoCIII) acts as a key inhibitor of lipoprotein lipase (LpL), and its reduction leads to more efficient clearance of triglycerides from the blood, thereby lowering plasma triglyceride levels and potentially reducing cardiovascular risk.

High levels of apoCIII slow down the breakdown of fat particles in your blood. This is often driven by insulin resistance. Managing insulin sensitivity through diet and exercise can naturally lower apoCIII levels, helping your body clear triglycerides more efficiently.